Pharmaceutical News and Articles

Risk Factors Associated With Child Food Allergy Identified

A combination of major and minor risk factors encompasses the most credible factors associated with development of childhood food allergy, according to a study

Overweight, Obesity Remained Highly Prevalent in U.S. Youths in 2024

Excess youth overweight and obesity remained highly prevalent in the United States in 2024, according to a study published online Feb. 10 in JAMA Network Open.

FDA Expands Tater Tot Recall Tied to Possible Plastic Contamination

TUESDAY, Feb. 17, 2026 A recall of frozen tater tots has expanded after federal officials warned that hundreds of thousands of pounds could contain pieces of pl

Exercise Can Reduce Depression, Anxiety Symptoms

Exercise can reduce depression and anxiety symptoms, according to a study published online Feb. 10 in The British Journal of Sports Medicine. Neil Richard Munro

Migraine Common in Women With Macromastia, Headache

Most women with macromastia and headache pursuing reduction surgery screen positive for migraine, according to a study published online Feb. 2 in Cephalalgia Re

Recommendations Developed for Primary Care Asthma Management in Veterans, Military Members

In a synopsis of a clinical practice guideline issued by the U.S. Department of Veterans Affairs and U.S. Department of Defense and published online Feb. 17 in

Couples Who Do This One Thing Feel More Satisfied And Secure Together

TUESDAY, Feb. 17, 2026 Couples who take time to slow down and enjoy the good moments they share may feel closer, argue less and feel more confident their relati

FDA Approves Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the Only EGFR-Targeted Therapy that can be Administered Once a Month

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

Baxdrostat Demonstrated Statistically Significant and Clinically Meaningful Reduction in Systolic Blood Pressure in Patients with Hard-to-Control Hypertension in the BaxHTN Phase III Trial

Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean sea